Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$ENTB Stem Cell Working To Treat Pets Cancer/Arthritis Update & FORM 8-K - CURRENT REPORT

$ENTB Stem Cell Working to Treat Pets Cancer/Arthritis

Thoroughbred (EIPH)

FORM 8-K - CURRENT REPORT

https://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=12090279

Zander Therapeutics is a Subsidiary of Entest Biomedical, Inc. - Regen BioPharma, Inc. (OTCQB:RGBP) is the Parent of Entest (ENTB-OTC)

RGBP has licensed various items to ENTB-NR2F6 being a Primary Focus.

NR2F6 is the Key to Zanders Success-Working Clinically to Treat Pets for Cancer/Arthritis - Thoroughbred Race Horses for (EIPH)

$ENTB has Shown Great Results - Silencing/Killing Cancer Cells Using Pets Own Blood

https://finance.yahoo.com/news/entest-biomedical-inc-subsidiary-zander-143400189.html

Other Recent News - Entest BioMedical's Chairman Discusses its Subsidiary, Zander Therapeutics, Inc.'s Progress with Small Molecule Immunotherapies for Treating Cancer and Arthritis in Dogs

Read More: https://finance.yahoo.com/news/entest-biomedicals-chairman-discusses-subsidiary-123000276.html

https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/4980668-entb-entest-biomedical-news-advancement-made-cancer-pet-lovers

Read More-

Great News -Further Advancement-Treating Cancer-Auto Immune Diseases-Lupus

https://seekingalpha.com/instablog/32618395-small-cap-solutions-llc/4989704-otcqb-rgbp-great-news-advancement-treating-cancer-auto-immune-diseases-lupus

Robert Kreh - Principal

Small Cap Solutions, LLC

(443) 567-2609

robkreh@smallcapsolutions.com

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.